CUA Educational Content

Update on the treatment landscape for Renal Cell Carcinoma (RCC) in Canada

Featuring: Laurence Albiges (Gustave Roussy Institute and University of Paris Saclay)

By participating in this program, participants can expect to:

  • review new therapies available in RCC
  • examine the impact on sequencing and patient management with new therapies in RCC
  • review patient cases/determine which patient type would benefit from an IO/IO vs. IO/TKI therapy in RCC

    ACCREDITATION

    This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.

     

    This program has received financial support from Pfizer in the form of an educational grant.

    The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

    For comments or information, email Corporate.office@cua.org

    Privacy Policy